- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Thank you
The Nomination Committee proposes unchanged Board remuneration -adjusted version
Due to the situation with the corona pandemic, XVIVO Perfusion's Nomination Committee, and the shareholders who have appointed the members in the Nomination Committee, has decided to withdraw the proposal that XVIVO Perfusion's Annual General Meeting on March 31, 2020 approves an increase in Board remuneration (item 12 on the agenda). Instead, the Nomination Committee, and the shareholders who have appointed the members in the Nomination Committee, proposes unchanged Board remuneration compared to 2019. The Nomination Committee's other proposals for the Annual General Meeting remain unchanged.
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, email@example.com
Magnus Nilsson, CEO, +46 31 788 2150, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:50 am CET on March 25, 2020.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.